Genetic testing firm 23andMe cuts 40% of jobs and halts therapeutic programs to save costs.

Genetic testing company 23andMe is cutting its workforce by 40%, affecting around 200 jobs, and halting the development of its therapeutic programs in a bid to save costs and refocus on its core business. CEO Anne Wojcicki plans to explore strategic alternatives like licensing and asset sales for the company’s therapeutics. The restructuring aims to save over $35 million annually.

November 12, 2024
6 Articles

Further Reading